title: A method that allows easy characterization of tumor-infiltrating lymphocytes.
abstract: A method was developed to compare the lymphocytic infiltrates in regressing vs. progressing experimental mouse tumors using a model for human papillomavirus-16 (HPV-16) oncoprotein-linked cancer. Tumor cells mixed with matrigel, composed of natural matrix substances that provide a basement membrane structure for adherent cells, were inoculated into mice vaccinated with an efficacious vaccine to the E7 oncoprotein or a vaccine to a control antigen. The tumor cells remained within the solidified gel and recruited a cellular infiltrate that could readily be analyzed upon removal of the gelatinous mass containing progressing or regressing tumors. The results show that tumors recruit activated CD8(+) T cells regardless of their antigen specificity. In regressing tumors expressing an appropriate target antigen for the vaccine-induced CD8(+) T cells, a strong increase of the tumor antigen-specific T cell population was observed over time. Progressing tumors that lacked the target antigen for the activated CD8(+) T cell population did not show this selective enrichment.
authors.affiliation: The Wistar Institute, 3601 Spruce St., 19104, Philadelphia, PA, USA.
authors.forename: D W
authors.initials: DW
authors.lastname: Kowalczyk
authors.forename: A P
authors.initials: AP
authors.lastname: Wlazlo
authors.forename: M
authors.initials: M
authors.lastname: Blaszczyk-Thurin
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Xiang
authors.forename: W
authors.initials: W
authors.lastname: Giles-Davis
authors.forename: H C
authors.initials: HC
authors.lastname: Ertl
mesh_terms: D000818:Animals; D000957:Antigens, Viral, Tumor / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines; D018925:Chemokines / Q000096:biosynthesis / Q000235:genetics; D003094:Collagen; D003601:Cytotoxicity Tests, Immunologic; D004338:Drug Combinations; D005260:Female; D007797:Laminin; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy; D009856:Oncogene Proteins, Viral / Q000276:immunology; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000276:immunology* / Q000628:therapy; D011509:Proteoglycans; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000276:immunology* / Q000628:therapy; D014765:Viral Vaccines
chemical_list: D000957:Antigens, Viral, Tumor; D019496:Cancer Vaccines; D018925:Chemokines; D004338:Drug Combinations; D007797:Laminin; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011509:Proteoglycans; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16; C059485:matrigel; D003094:Collagen